New pharmacogenomic paradigm in breast cancer treatment

Journal of Clinical Oncology

Volumn 28, Issue 31, 2010, Pages 4665-4666

  Offit, Kenneth ^a   Robson, Mark E ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EXEMESTANE; LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTROGEN; ONCOPROTEIN; TCL1A PROTEIN, HUMAN;

BREAST CANCER; CHROMOSOME 14; EDITORIAL; GENE LOCUS; GENOME ANALYSIS; GENOTYPE; HUMAN; MUSCULOSKELETAL DISEASE; PHARMACOGENOMICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM; TREATMENT RESPONSE; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; METHODOLOGY; NOTE; PHARMACOGENETICS; RISK;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTROGENS; FEMALE; HUMANS; ODDS RATIO; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; RESEARCH DESIGN;

EID: 78149244080     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.2926     Document Type: Editorial

References (10)

1. Stegmeier F, Warmuth M, Sellers WR, et al: Targeted cancer therapies in the twenty-first century: Lessons from imatinib. Clin Pharmacol Ther 87:543-552, 2010
2. Garber JE, Offit K: Hereditary cancer predisposition syndromes. J Clin Oncol 23:276-292, 2005 (Pubitemid 46206879)
3. Huang RS, Ratain MJ: Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 59:42-55, 2009
4. Stadler ZK, Thom P, Robson ME, et al: Genome-wide association studies of cancer. J Clin Oncol 10.1200/JCO.2009.25.7816 [epub ahead of print on June 28, 2010]
5. Ingle JN, Schaid DJ, Goss PE, et al: Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28:4674-4682, 2010
6. Din OS, Dodwell D, Wakefield RJ, et al: Aromatase inhibitor-induced arthralgia in early breast cancer: What do we know and how can we find out more? Breast Cancer Res Treat 120:525-538, 2010
7. Offit K: Breast cancer single-nucleotide polymorphisms: Statistical significance and clinical utility. J Natl Cancer Inst 101:973-975, 2009
8. Jakobsdottir J, Gorin MB, Conley YP, et al: Interpretation of genetic association studies: Markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet 5:e1000337, 2009
9. Briot K, Tubiana-Hulin M, Bastit L, et al: Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: The ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 120:127-134, 2010
10. Gnant M, Mlineritsch, Stoeger H, et al: Mature results from ABCSG-12:Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrineresponsive early breast cancer. J Clin Oncol 28:75s, 2010 (suppl; abstr 533)